Highlights of Q3 FY 2019-20 (Consolidated):
- The Net Profit after Tax during the period stood at Rs. 10.81 crore, up by 21.3 per cent from Rs. 8.91 crore net profit registered in the corresponding period of FY’2018-19.
- Net Sales Revenue recorded a growth of 8.9 per cent at Rs. 226.91 crore in Q3’FY 2019-20 as compared to Rs. 208.46 crore in the corresponding quarter of the previous fiscal.
- EBIDTA was up by 3.3 per cent in Q3’ FY 2019-20 at Rs. 19.90 crores (Rs. 19.27 crores )and Cash profit during the same period was up by around 2.8 per cent at Rs. 19.36 crores (Rs. 18.84 crores).
- Net Profit before tax went up by 19.7 per cent in Q3’ FY 2019-20 at Rs. 10.82 crore (Rs. 9.04 crore). Domestic sales were up by 22.2 percent at Rs. 136.76 crore in Q3’FY2019-20 as compared to Rs. 111.90 crore in the corresponding quarter of the previous fiscal.
- Overall API sales were up by 9.8 percent at Rs. 131.96 crores in Q3 FY 2019-20, constituting 58 per cent of the total turnover. API sales in the domestic market registered an impressive growth of 76 percent at Rs. 42.56 crore.
- Domestic sales in Q3’FY 2019-20 for Atorvastatin Calcium rose by 146 percent and Montelukast by 70 percent vis-a-vis the corresponding quarter of the previous fiscal.
- In Export market, Rosuvastatin registered growth of 171 per cent and Loratadine of 25 percent in Q3’FY 2019-20 vis-a-vis Q3 of the previous fiscal.
- Nebulisers sales jump up by 89 percent in Q3’FY 2019-20 as compared to Q3of previous fiscal.
- The company has sold around 110 million Blood Glucose testing strips in first nine monthsof FY 2019-20 registering a growth of 24 percent as against the corresponding period of the previous fiscal and has achieved a milestone of 400 million glucose testing strips till date.
- Branded Formulations’ sales have recorded a good growth of 35 percent in Q3 FY’2019-20 vis-a-vis Q3 of the previous fiscal.
- Over the Counter (OTC) business has recorded growth of 22% in its sales revenue during the Q3’FY 2019-20, however, Isabgol and other small base brands grew by 50 per cent and 61 per cent respectively in the same period. This Business has been strengthened further with many new products in the nutritional and preventive healthcare segments.
- Internal accruals stream continued to get stronger, be it on operating profit front or cash profit front.
New Delhi, February 17, 2020: Morepen Laboratories Ltd. has reported a 21.3 per cent rise in its Net Profit after Tax (Consolidated) in Q3 FY2019-20 at Rs. 10.81 crore as compared to Rs. 8.91 crore net profit registered in the corresponding quarter of the previous fiscal. Net sales Revenue (Consolidated) during Q3 FY 2019-20 stood at Rs. 226.91 crore, registering a growth of 8.9 per cent as compared to the Net Sales Revenue of Rs. 208.46 crore in the corresponding quarter of the previous fiscal.
Total Revenue (Consolidated) in Q3 FY2019-20 rose to Rs. 234.65 crore (Rs. 214.59 crore) registering a jump of 9.4 per cent. EBIDTA was up by 3.3 per cent in Q3’ FY 2019-20 at Rs. 19.90 crores (Rs. 19.27 crores) and Cash profit during the same period was up by around 2.8 per cent at Rs. 19.36 crores (Rs. 18.84 crores).The Net Profit Before Tax (Consolidated) posted a growth of 19.7 percent in Q3 FY2019-20 at Rs. 10.82 crore compared to Rs. 9.04 crore in Q3 of previous fiscal.
The bulk drugs (API) segment contributed around 58 per cent to the company’s total turnover in Q3 FY 2019-20. The company’s expanding domestic reach assisted in achieving a higher topline in Q3 FY2019-20. API sales in the domestic market registered a growth of 76 per cent at Rs. 42.56 crore in Q3FY2019-20. Domestic sales for Atorvastatin Calcium rose by 146 percent at Rs. 3.38 crore and Montelukast by 70 percent at Rs. 16.78 crore in Q3 FY2019-20 vis-a-vis the corresponding quarter of the previous fiscal. API’s Export sales registered a decline of 7 per cent at Rs. 89.39 crore in Q3 FY2019-20. Export sales for Rosuvastatin rose by 171 percent at Rs. 10.83 crore and Loratadine by 25 percent at Rs. 39.24 crore in Q3 FY2019-20 vis-a-vis the corresponding quarter of the previous fiscal.
This was disclosed by Mr. Sushil Suri, Chairman and Managing Director, Morepen Laboratories Ltd., after the financial results board meeting for Q3 and nine months ended December 31st, 2019 here on Friday. “Our investment in the manufacturing of medical devices in India has already started showing results. Company is all geared up for increasing its focus on backward integration and capacity enhancement in order to reduce its dependency on imports from across the globe, particularly China, in the coming years,” Mr. Suri said.
Synopsis of Nine months (9M) and Third Quarter (Q3) FY 2019- 20-Performance (Consolidated):
Rs. in Crores
| Q3 | 9M | |||||
| Particulars | FY 2018-19 | FY 2019-20 | % Growth | FY 2018-19 | FY 2019-20 | % Growth |
| Net Sales Revenue | 208.46 | 226.91 | 8.9% | 541.59 | 637.26 | 17.7% |
| Total Revenue | 214.59 | 234.65 | 9.4% | 552.47 | 654.15 | 18.4% |
| Expenditure | 195.32 | 214.75 | 9.9% | 504.05 | 596.77 | 18.4% |
| EBIDTA | 19.27 | 19.90 | 3.3% | 48.41 | 57.38 | 18.5% |
| Interest | 0.43 | 0.54 | 27% | 1.18 | 1.36 | 15.1% |
| Cash Surplus | 18.84 | 19.36 | 2.8% | 47.23 | 56.02 | 18.6% |
| Net Profit before tax | 9.04 | 10.82 | 19.7% | 18.47 | 27.74 | 50.2% |
| Net Profit after tax | 8.91 | 10.81 | 21.3% | 18.35 | 22.55 | 22.9% |
The Branded formulations registered a good growth of 35 percent in Q3 FY 2019-20 at Rs. 11.53 crore vis-a-vis the corresponding quarter of the previous fiscal. Sale of Gastro category increased by 66 percent and Antibiotics by 18 percent in Q3’FY2019-20 vis-a-vis the corresponding quarter of the previous fiscal. The Branded generics maintained almost the same pace at Rs. 23.99 crore in Q3’FY2019-20 vis-a-vis the corresponding quarter of the previous fiscal
The growth in overall Home Diagnostic Segment remained consistent at Rs. 42.87 crore in Q3’FY2019-20 vis-a-vis the corresponding quarter of the previous fiscal. Nebulisers and other range products recorded highest growth in the quarter @ 89 percent and 28 percent respectively.
The OTC business grew by 22 per cent in Q3 FY 2019-20 at Rs. 17.65 crore vis-a-vis the corresponding quarter of the previous fiscal. Isabgol and other new small brands grew by 50 per cent and 61 per cent, respectively. OTC Business witnessed launch of many new products to its Health basket including Active Smile, Dr. Morepen Daily, MTP Kit, Vcalci tablet, Vcalci D3 shot, Clean & Pure, Liv Healthy, Head-X, Dr. Morepen Aid, Dr. Morepen Buds, COLD-EX, Paachan-Arishta, Adult Nasal Spray, Burnol antiseptic cream, Burnol antiseptic solution, Burnol plus, Quickchek advance midstream test, Pain-X spas, Pain-X combi suspension, Pain-X max gel, Pain-X ortho oil, Exygra spray, Quit & Out and Nourish skin cream in various new product categories. New products are expected to add significantly to the company’s topline in the coming quarters.
In the nine months ended December 31, 2019, Morepen Laboratories. has reported a net sales revenue (consolidated) of Rs. 637.26 crore, registering a growth of 17.7 per cent vis-a-vis net sales revenue of Rs. 541.59 crore in the corresponding quarter of the previous fiscal. The company’s EBIDTA in 9M’ FY 2019-20 increased by 18.5 per cent at Rs. 57.38 crore and cash profit increased by 18.6 per cent at Rs. 56.02 crore as against Rs. 48.41 crore and Rs. 47.23 crore, respectively, in the corresponding nine-month period of the previous fiscal.
The Net Profit Before Tax (consolidated) for 9M FY 2019-20 stood at Rs. 27.74 crore, registering a rise of 50.2 per cent. The Net profit after tax (PAT) increased by 22.9 per cent at Rs. 22.55 crore compared to Rs. 18.35 Crore in the corresponding period of the previous fiscal. This is despite a one-time hit of Rs. 5.15 crore taken by the company by writing off MAT credit entitlement in line with the new Taxation Laws (Amendment) Ordinance 2019 in Q2 FY 2019-20.
API sales in domestic market registered a growth of 35 per cent at Rs. 99.37 crore and 22 percent in export market at Rs. 261.38 crores sales in the nine months ended December 31st, 2019.The overall Home Diagnostic Segment recorded total sales of Rs. 128.42 crore in the nine months ended December 31st, 2019, registering a rise of 15 per cent vis-a-vis corresponding period of the previous fiscal. Morepen Labs’ branded formulations business have recorded a growth of 21% in the nine months ended December 31st, 2019 by achieving a sales revenue of Rs. 32.73 crore compared to the same period previous fiscal . Branded Generics have reported a decline of 6 percent .OTC Business has recorded growth of 15% in its sales revenue in the nine months ended December 31st, 2019.
Corporate Comm India (CCI Newswire)
